Novartis' Cosentyx shows almost all psoriasis patients rapidly regain skin clearance following a treatment pause
- Details
- Category: Novartis
Novartis has announced a new analysis showing that moderate-to-severe psoriasis patients treated with Cosentyx® (secukinumab) rapidly regain clear or almost clear skin (Psoriasis Area Severity Index, PASI 90 to 100) following relapse during a treatment pause[1]. The analysis also showed no anti-secukinumab antibodies were observed during retreatment[1].
Phase III APHINITY study shows Roche's Perjeta® regimen helped people with an aggressive type of early breast cancer live longer without their disease returning compared to Herceptin® and chemotherapy
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY), the Breast International Group (BIG), Breast European Adjuvant Study Team (BrEAST) and Frontier Science Foundation (FS) have announced positive results from the phase III APHINITY study. The study met its primary endpoint and showed that adjuvant (after surgery) treatment with the combination of Perjeta® (pertuzumab), Herceptin® (trastuzumab) and chemotherapy
Bristol-Myers Squibb expands focus on precision medicine with investment and planned collaboration with GRAIL
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) announced its equity investment and plans for a research collaboration with GRAIL Inc., a life sciences company whose mission is to detect cancer early when it potentially can be cured. By combining the power of high intensity cancer DNA sequencing, leading edge computer science and large clinical studies into a diagnostic platform, GRAIL aims to
Johnson & Johnson completes acquisition of Abbott Medical Optics
- Details
- Category: Johnson & Johnson
Johnson & Johnson (NYSE: JNJ) has completed the acquisition of Abbott Medical Optics (AMO), a wholly-owned subsidiary of Abbott. The all-cash $4.325 billion acquisition was originally announced Sept. 16, 2016, and includes ophthalmic products in three areas of patient care: cataract surgery, laser refractive surgery and consumer eye health.
FDA approves once-daily Qtern (dapagliflozin and saxagliptin) tablets for adults with type-2 diabetes
- Details
- Category: AstraZeneca
AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved once-daily Qtern (10mg dapagliflozin and 5mg saxagliptin) for the treatment of type-2 diabetes. The new medicine is indicated as an adjunct to diet and exercise to improve glycaemic (blood sugar level) control in adults with type-2 diabetes who have inadequate control with dapagliflozin (10mg) or who are already treated with dapagliflozin and saxagliptin.
Bristol-Myers Squibb expands International Immuno-Oncology Network (II-ON)
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) today announced that Columbia University Medical Center and Peter MacCallum Cancer Centre (Peter Mac) have joined the International Immuno-Oncology Network (II-ON), a global peer-to-peer collaboration between Bristol-Myers Squibb and academia that aims to advance Immuno-Oncology (I-O) science and translational medicine to improve patient outcomes.
Ronald E. Blaylock elected to Pfizer's Board of Directors
- Details
- Category: Pfizer
Pfizer Inc. has announced the election of Ronald E. Blaylock to its Board of Directors, effective immediately. Mr. Blaylock was also appointed to the Corporate Governance and Science and Technology Committees of Pfizer's Board.
More Pharma News ...
- Novartis drug Zykadia receives FDA Priority Review for first-line use in patients with ALK+ metastatic NSCLC
- Another record year for Bayer - good progress with the acquisition of Monsanto
- Bristol-Myers Squibb appoints three new independent directors
- AstraZeneca enters agreement with TerSera Therapeutics for Zoladex in the US and Canada
- Siliq (brodalumab) approved by the US FDA for adult patients with moderate-to-severe plaque psoriasis
- Boehringer Ingelheim and Weill Cornell Medicine announce new collaboration to discover next generation COPD treatments
- Phase III COMPASS study with Bayer's rivaroxaban (Xarelto®) shows overwhelming efficacy and meets primary endpoint early